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Abstract
Following an application from Unilever NV, submitted for authorisation of a health claim pursuant to
Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Ireland, the EFSA
Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the
scientific substantiation of a health claim related to black tea and maintenance of normal endothelium-
dependent vasodilation. The scope of the application was proposed to fall under a health claim based
on newly developed scientific evidence. The food proposed by the applicant as the subject of the
health claim is black tea beverages, either freshly prepared or reconstituted from water extract
powders of black tea, characterised by the content of flavanols (expressed as catechins plus
theaflavins) of at least 30 mg per 200 mL serving. The Panel considers that black tea characterised by
the content of flavanols (expressed as catechins plus theaflavins) is sufficiently characterised. The
claimed effect proposed by the applicant is ‘improvement of endothelium-dependent vasodilation’. The
Panel considers that maintenance of normal endothelium-dependent vasodilation is a beneficial
physiological effect. Of the five human intervention studies provided on the chronic effect of black tea
consumption on endothelium-dependent vasodilation, two investigated the effect after regular
consumption of black tea for a sufficiently long time period (i.e. at least 4 weeks). These two studies
did not allow an effect of black tea on endothelium-dependent vasodilation to be established. The
Panel concludes that a cause and effect relationship has not been established between the
consumption of black tea and maintenance of normal endothelium-dependent vasodilation.
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Summary
Following an application from Unilever NV, submitted for authorisation of a health claim pursuant to
Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Ireland, the EFSA
Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the
scientific substantiation of a health claim related to black tea and maintenance of normal endothelium-
dependent vasodilation.
The scope of the application was proposed to fall under a health claim based on newly developed
scientific evidence.
The general approach of the NDA Panel for the evaluation of health claims applications is outlined
in the EFSA general guidance for stakeholders on health claim applications and the guidance on the
scientific requirements for health claims related to antioxidants, oxidative damage and cardiovascular
health.
The food proposed by the applicant as the subject of the health claim is black tea beverages, either
freshly prepared or reconstituted from water extract powders of black tea, characterised by the
content of flavanols (expressed as catechins plus theaflavins) of at least 30 mg per 200 mL serving.
The Panel considers that black tea characterised by the content of flavanols (expressed as catechins
plus theaflavins) of ≥ 30 mg/200 mL serving, which is the subject of the health claim, is sufficiently
characterised.
The claimed effect proposed by the applicant is ‘improvement of endothelium-dependent
vasodilation’. The proposed target population is ‘adults in the general population’. The Panel considers
that maintenance of normal endothelium-dependent vasodilation is a beneficial physiological effect.
The applicant identified as directly pertinent to the claim five human intervention studies on the
effect of black tea consumption on endothelium-dependent vasodilation measured in fasting conditions
after regular consumption of black tea (chronic effect) and four human intervention studies on the
acute effect of black tea consumption on endothelium-dependent vasodilation after regular
consumption of black tea (acute-in-chronic effect). In addition, the applicant provided eight human
intervention studies on the acute effects of tea beverages on endothelium-dependent vasodilation as
supportive evidence. The applicant also submitted meta-analyses of the chronic, acute-in-chronic
studies and acute studies, both individually and combined.
Out of the five human intervention studies provided on the chronic effect of black tea consumption
on endothelium-dependent vasodilation, only two investigated the effect after regular consumption of
black tea for a sufficiently long time period (i.e. at least four weeks).
In one of these studies, an effect of black tea consumption not only on endothelium-dependent
vasodilation but also on endothelium-independent vasodilation was observed. Therefore, this study did
not allow conclusions to be drawn on whether the effects of black tea consumption on vasodilation
were endothelium dependent or mediated via endothelium-independent pathways. The Panel considers
that no conclusions can be drawn from this study on the effect of black tea consumption on
endothelium-dependent vasodilation. The second study in which black tea was consumed for 6 months
did not show an effect of black tea consumption on endothelium-dependent vasodilation.
In the absence of studies allowing an effect of black tea consumption to be established on
endothelium-dependent vasodilation in fasting conditions in healthy individuals after regular
consumption of the food for at least 4 weeks, the Panel considered that studies of shorter duration, on
an acute effect of black tea consumption with or without preceding continued consumption of the
food, or in patients, as well as the meta-analysis provided by the applicant cannot be used for the
scientific substantiation of the claim.
In weighing the evidence, the Panel took into account that the two studies which were provided by
the applicant and which investigated the effect of black tea consumption on endothelium-dependent
flow-mediated dilation in fasting conditions after regular consumption of the food for at least four
weeks did not allow an effect of black tea on endothelium-dependent vasodilation to be established.
On the basis of the data provided, the Panel concludes that a cause and effect relationship has not
been established between the consumption of black tea and maintenance of normal endothelium-
dependent vasodilation.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
Regulation (EC) No 1924/20061 harmonises the provisions that relate to nutrition and health claims,
and establishes rules governing the Community authorisation of health claims made on foods. As a
rule, health claims are prohibited unless they comply with the general and specific requirements of this
Regulation, are authorised in accordance with this Regulation and are included in the lists of
authorised claims provided for in Articles 13 and 14 thereof. In particular, Article 13(5) of this
Regulation lays down provisions for the addition of claims (other than those referring to the reduction
of disease risk and to children’s development and health) which are based on newly developed
scientific evidence, or which include a request for the protection of proprietary data, to the Community
list of permitted claims referred to in Article 13(3).
According to Article 18 of this Regulation, an application for inclusion in the Community list of
permitted claims referred to in Article 13(3) shall be submitted by the applicant to the national
competent authority of a Member State, which will make the application and any supplementary
information supplied by the applicant available to the European Food Safety Authority (EFSA).
1.2. Interpretation of the Terms of Reference
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with
Article 16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an
opinion on the scientific substantiation of a health claim related to: black tea and improvement of
endothelium-related vasodilation.
The present opinion does not constitute, and cannot be construed as, an authorisation for the
marketing of black tea, a positive assessment of their safety, nor a decision on whether black tea is, or
is not, classified as a foodstuff. It should be noted that such an assessment is not foreseen in the
framework of Regulation (EC) No 1924/2006.
It should also be highlighted that the scope, the proposed wording of the claim and the conditions
of use as proposed by the applicant may be subject to changes, pending the outcome of the
authorisation procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006.
2. Data and methodologies
2.1. Data
Information provided by the applicant
Food/constituent as stated by the applicant
According to the applicant, the food for which the health claim is made is ‘catechins and theaflavins
found in beverages prepared from the leaves of Camellia sinensis (L.) Kuntze’. Following EFSA’s request
for clarification, the applicant indicated that the food for which the health claim is made is ‘black tea
beverages characterised by the content of flavanols (expressed as catechins plus theaflavins)’.
Health relationship as claimed by the applicant
According to the applicant, the claimed effect relates to: ‘improvement of endothelium-dependent
vasodilation’.
Mechanism by which the food/constituent could exert the claimed effect as proposed by
the applicant
The applicant claims that ‘the available evidence demonstrates that flow-mediated dilation is
increased acutely after consumption of tea flavanols and this effect is still present after regular
consumption for longer periods of time’.
Wording of the health claim as proposed by the applicant
The applicant has proposed the following wording for the health claim: ‘improves endothelium-
dependent vasodilation which contributes to healthy blood flow’.
1 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health
claims made on foods. OJ L 404, 30.12.2006, p. 9–25.
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Specific conditions of use as proposed by the applicant
According to the applicant, the target population for the intended health claim is adults in the
general population and a daily intake of ~ 160 mg tea flavanols (approx. 1,090 mL (5–6 servings) of
black tea) is required to obtain a physiologically relevant increase of 1% in flow-mediated dilation
(FMD).
Data provided by the applicant
Health claim application on tea flavanols and improvement of endothelium-related vasodilatation
pursuant to Article 13.5 of Regulation 1924/2006, presented in a common and structured format as
outlined in the Scientific and technical guidance for the preparation and presentation of applications for
authorisation of health claims (EFSA NDA Panel, 2011a).
As outlined in the General guidance for stakeholders on health claim applications (EFSA NDA Panel,
2016), it is the responsibility of the applicant to provide the totality of the available evidence.
2.2. Methodologies
The general approach of the Dietetic Products, Nutrition and Allergies (NDA) Panel for the
evaluation of health claims applications is outlined in the EFSA general guidance for stakeholders on
health claim applications (EFSA NDA Panel, 2016).
The scientific requirements for health claims related to antioxidants, oxidative damage and
cardiovascular health are outlined in a specific EFSA guidance (EFSA NDA Panel, 2011b).
The application contains data claimed as confidential:
a) Unpublished consumer research.
b) Analytical technique for the determination of the flavin content of black and green teas.
c) Unpublished compositional data of a range of black and green teas.
3. Assessment
3.1. Characterisation of the food/constituent
The food proposed by the applicant as the subject of the health claim is ‘catechins and theaflavins
found in beverages prepared from the leaves of Camellia sinensis (L.) Kuntze’.
The main catechins in tea include (-)-epigallocatechin gallate, (-)-epigallocatechin, (-)-epicatechin-3-
O-gallate, (-)-epicatechin, (+)-gallocatechin and (+)-catechin. The major theaflavins are theaflavin,
theaflavin-3-O-gallate, theaflavin-3’-O-gallate and theaflavin-3,3’-O-digallate. Black tea also contains
thearubigins, believed to constitute about 60% of black tea solids (Haslam, 2003).
Upon a request from EFSA to clarify whether the claim refers to tea flavanols (including catechins,
theaflavins and thearubigins), to a fixed combination of catechins and theaflavins in tea or to tea
beverages made from the leaves of Camellia sinensis (L.) Kuntze characterised by their content in
catechins and theaflavins, the applicant replied that the food that is the subject of the claim is black
tea beverages, either freshly prepared or reconstituted from water extract powders of black tea,
characterised by the content of flavanols (expressed as catechins plus theaflavins) of at least 30 mg
per 200 mL serving.
Catechins and theaflavins can be measured in foods by well-established methods.
The Panel notes that catechins are absorbed after oral consumption, whereas the absorption of
theaflavins in the small intestine is low (Mulder et al., 2001). Theaflavins persist to the colon, where
they undergo catabolism by gut microbiota (van Duynhoven et al., 2011; Chen et al., 2012; Del Rio
et al., 2013). There is some evidence that the gut microbial catabolites of black tea polyphenols are
recirculated into plasma (van Duynhoven et al., 2014).
The Panel considers that black tea characterised by the content of flavanols (expressed as
catechins plus theaflavins) of ≥ 30 mg/200 mL which is the subject of the health claim is sufficiently
characterised.
3.2. Relevance of the claimed effect to human health
The claimed effect proposed by the applicant is ‘improvement of endothelium-related vasodilation’.
The proposed target population is ‘adults in the general population’.
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Improvement of endothelium-dependent (ED) vasodilation, which is a specific endothelial function,
can be measured in vivo in humans using well-accepted methods. The capacity of blood vessels to
respond to physical and chemical stimuli in the lumen confers the ability to self-regulate tone and to
adjust blood flow and distribution in response to changes in the local environment. Many blood vessels
respond to an increase in flow, or more precisely shear stress, by dilating. This phenomenon is
designated as FMD. A principal mediator of FMD is endothelium-derived nitric oxide (NO). Endothelial
denudation or treatment with a nitric oxide synthase (NOS) inhibitor abolishes FMD in a variety of
arterial vessels. Endothelium-derived prostanoids and the putative endothelium-derived hyperpolarising
factor have also been implicated as backup mechanisms mediating changes in arterial diameter in
response to shear stress, so that there may be some redundancy in the system in order to ensure an
appropriate response of blood vessels to shear stress. ED vasodilation contributes to the maintenance
of an adequate blood flow to body cells and tissues.
ED vasodilation can be assessed in vivo at different points of the arterial tree using well-established
methods (e.g. the FMD technique). Endothelium-independent vasodilation (EIVD) of the brachial artery
induced by exogenous NO donors (e.g. after the sublingual administration of nitroglycerin) is also
measured as control (Corretti et al., 2002; Thijssen et al., 2011).
The effect of a food/constituent on ED vasodilation can be expressed as changes in ED-FMD either
in fasting conditions after regular consumption of the food/constituent, or as acute changes in ED-FMD
occurring shortly after consumption of the food/constituent. A sustained increase in ED vasodilation in
fasting conditions in response to an intervention (regular consumption of a food/constituent for at least
four weeks) is a beneficial physiological effect.
Markers of plasma NO status (e.g. nitrite/nitrosyl species measured by reductive gas-phase
chemiluminescence) can provide evidence on the mechanisms by which the food/constituent could
exert the claimed effect, but cannot be used alone for the substantiation of the claim.
The Panel considers that maintenance of normal ED vasodilation is a beneficial physiological effect.
3.3. Scientific substantiation of the claimed effect
The applicant performed a literature search in Medline, Embase, Chemical Abstracts and Biosis
(from starting date of the databases until July 2016) with the following key words: (tea or black tea or
green tea or flavonoid or tea extract or tea component or tea solid or Camellia sinensis) and (flow-
mediated or flow mediated or FMD or endothelial function or endothelial dysfunction or endothelium-
dependent or blood flow or arterial stiffness or vascular resistance or circulat* or micro-circulat* or
microcirculat* or vasodilat* or dilat*). No restrictions were applied. Hand searches were also
performed.
In the original application, the applicant had identified 15 published and three unpublished human
intervention studies as well as one published and one unpublished meta-analysis as pertinent to the
claim. These included studies investigating the effects of green tea, black tea or tea flavanols on ED-
FMD. Following EFSA’s request and the applicant’s clarification that the food that is the subject of the
claim is black tea beverages, the applicant identified as directly pertinent to the claim five human
intervention studies on the effect of black tea consumption on ED-FMD measured in fasting conditions
after regular consumption of black tea (chronic effect) (three published (Duffy et al., 2001; Hodgson
et al., 2005; Bohn et al., 2014), two unpublished (Mulder et al., 2013, unpublished; Mulder and
Dutman, 2014, unpublished)) and four human intervention studies on the acute effect of black tea
consumption on ED-FMD after regular consumption of black tea (acute-in-chronic effect) (two
published (Grassi et al., 2009, 2016) and two unpublished (Mulder et al., 2013, unpublished; Mulder
and Dutman, 2014, unpublished)). In addition, the applicant provided eight human intervention studies
on the acute effects of tea beverages on ED-FMD (Duffy et al., 2001; Hodgson et al., 2005; Ardalan
et al., 2007; Lorenz et al., 2007; Jochmann et al., 2008; Mulder and Dutman, 2014, unpublished;
Mulder et al., 2016, unpublished) as supportive evidence. The applicant also submitted meta-analyses
of the chronic, acute-in-chronic studies and acute studies, both individually and combined.
The Panel notes that the study by Ardalan et al. (2007) was not randomised and consisted of a
sequential administration of the test products. The Panel considers that no conclusions can be drawn
from this study for the substantiation of the claim.
The Panel considers that human intervention studies in healthy individuals on the effect of black tea
consumption on ED-FMD measured in fasting conditions after regular consumption of black tea of at
least 4 weeks are directly pertinent to the claim, while studies of shorter duration, on the acute effects
of black tea on ED-FMD with or without preceding regular consumption of the food or studies in
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patients can provide additional information, but are not sufficient on their own to establish an effect of
the food on ED vasodilation.
Among the studies provided by the applicant, two investigated the effect of black tea consumption
on ED-FMD measured in fasting conditions after regular consumption of black tea of at least 4 weeks.
Hodgson et al. (2002) studied the effect of consuming black tea for 4 weeks in five servings per
day (250 mL per serving; in total 1250 mL, estimation of the flavanol content provided by the
applicant complying with the specifications for the food being the subject of the claim; claimed as
confidential) in 21 subjects (10 in black tea group and 11 in hot water group, mean age ~59 years, 16
men), who were regular tea drinkers, in a randomised, single-blind (blinded to staff performing
measurements), parallel design. The infusion time for black tea was one minute with constant
movement. During the study period, subjects were instructed not to consume any caffeinated
beverages other than the tea beverage to which they were assigned and not to change their habitual
diet.
Measurements of endothelial function of the left brachial artery after an overnight fast were
obtained at the end of the baseline period and at the end of the intervention period. EIVD of the
brachial artery was measured following administration of 400 lg of sublingual glyceryl trinitrate (GTN)
spray. Analysis of ED-FMD and of GTN-mediated dilation was carried out using a semi-automated
edge-detection software system. The sample size of the study was sufficient to detect an absolute
1.5% improvement in FMD and an absolute 4.5% improvement in the response to GTN with an 80%
power (a = 0.05).
General linear models were used to examine differences in post-intervention values after
adjustment for baseline values. The Panel notes that baseline FMD was different between groups
(mean  SE: 5.1%  1.0% in the black tea group and 6.1  0.9% in the hot water group).
Consumption of black tea resulted in a significant increase in FMD with an absolute change of 2.3%
(95% CI 0.7 to 3.9%). In one subject in the tea group, a large increase in ED-FMD was observed.
When this subject was removed from analysis, the increase in ED-FMD still remained significant.
The increase in the response to GTN was also significantly higher in the black tea group compared
with the hot water group (mean  SE: 22.1  2.0% vs. 16.9  0.9%, p = 0.03). Upon a request from
EFSA to comment on the biological plausibility of the differential responses to GTN in the study
groups, the applicant explained that the finding may potentially be related to the high dose of GTN
used in this study (400 lg while 25 lg is the dose generally recommended), which, according to the
applicant, elicits very large and therefore inherently noisier brachial artery dilation responses and might
lead to spurious conclusions. The Panel notes that even if the dose of GTN used in the study might
have led to more variable brachial artery dilation responses among individuals, this would have not
been expected to be different between groups and cannot explain the differential response to GTN
administration of the black tea and the hot water group.
The Panel notes that this study showed an effect of black tea consumption for 4 weeks on
vasodilation. However, owing to the significant differences observed between groups on EIVD, the
Panel notes that results of the study do not allow conclusions to be drawn on whether the effects of
black tea consumption on vasodilation were ED or mediated via endothelium-independent pathways.
The Panel considers that no conclusions can be drawn from this study on the effect of black tea
consumption on ED vasodilation.
Bohn et al. (2014) performed a randomised, two-arm, placebo-controlled, double-blind, 6-month
parallel trial to investigate the long-term effects of daily consumption of black tea in 111 healthy
subjects who were regular tea drinkers. The primary outcome was changes in 24 h systolic blood
pressure, upon which also sample size calculations were based. ED-FMD was a secondary outcome.
The participants were randomly allocated to drink three servings of black tea prepared from black
tea powder by adding 100–200 mL of hot water (containing 429 mg of polyphenols assessed as gallic
acid equivalents and 96 mg of caffeine/day) or a placebo beverage containing no tea solids, but was
matched in flavour and caffeine content. During the study period, subjects were asked to restrict the
intake of tea, coffee, red wine, chocolate and fruit juices.
ED-FMD was measured at baseline and at 3 and 6 months of the intervention after overnight
fasting and was assessed as maximum diameter (max. FMD diameter) and maximum dilation relative
to vessel size (Peak FMD). Analysis was carried out using a semi-automated edge-detection software
system. EIVD was not measured.
Data were analysed using a linear mixed model. Statistical analysis were performed on the per
protocol population (77 participants (38 black tea group and 39 placebo group) mean age ~ 56 years,
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50 females) that was defined as all participants who completed the 6-month study, had measurements
performed for the relevant outcome and consumed at least 70% of the study product.
No statistically significant changes in ED-FMD were found after having consumed black tea for 3
and for 6 months.
The Panel notes that this study did not show an effect of black tea consumption on ED-FMD.
The Panel notes that none of studies showed an effect of black tea consumption on ED vasodilation
in fasting conditions in healthy individuals after regular consumption of the food for at least 4 weeks.
In this context, studies of shorter duration (i.e. one week (Mulder et al., 2013, unpublished; Mulder
and Dutman, 2014, unpublished; Grassi et al., 2016)), on an acute effect of black tea consumption
with or without preceding regular consumption of the food (Lorenz et al., 2007; Jochmann et al.,
2008; Grassi et al., 2009; Mulder et al., 2013, unpublished; Mulder and Dutman, 2014, unpublished;
Grassi et al., 2016; Mulder et al., 2016, unpublished), or in patients (Duffy et al., 2001; Hodgson et al.,
2005), as well as the meta-analyses provided by the applicant cannot be used for the scientific
substantiation of the claim.
Weighing of the evidence
In weighing the evidence, the Panel took into account that the two studies from which conclusions
can be drawn for the effect of black tea consumption on ED-FMD in fasting conditions after regular
consumption of the food for at least 4 weeks did not show effect of black tea on ED vasodilation.
The Panel concludes that a cause and effect relationship has not been established between the
consumption of black tea and maintenance of normal ED vasodilation.
4. Conclusions
On the basis of the data presented, the Panel concludes that:
• The food/constituent, black tea characterised by the content of flavanols (expressed as
catechins plus theaflavins) of ≥ 30 mg/200 mL which is the subject of the health claim, is
sufficiently characterised.
• The claimed effect proposed by the applicant is ‘improvement of endothelium-dependent
vasodilation’. The target population proposed by the applicant is ‘adults in general population’.
Maintenance of normal ED vasodilation is a beneficial physiological effect.
• A cause and effect relationship has not been established between the consumption of black
tea and maintenance of normal ED vasodilation.
Steps taken by EFSA
Health claim application on ‘tea flavanols’ and ‘improvement of endothelium-dependent vasodilation’
pursuant to Article 13(5) of Regulation (EC) No 1924/2006 (Claim serial No: 0458_IE). Submitted by
Unilever N.V., Weena 455, 3013 AL Rotterdam, The Netherlands.
1) This application was received by EFSA on 16/5/2017.
2) The scope of the application was proposed to fall under a health claim based on newly
developed scientific evidence.
3) The scientific evaluation procedure started on 27/6/2017.
4) On 6/9/2017, the Working Group on Claims of the NDA Panel agreed on a list of questions
for the applicant to provide additional information to accompany the application. The
scientific evaluation was suspended on 2/10/2017 and was restarted on 16/10/2017, in
compliance with Article 18(3) of Regulation (EC) No 1924/2006.
5) During its meeting on 13/12/2017, the NDA Panel, having evaluated the data, adopted an
opinion on the scientific substantiation of a health claim related to black tea and
improvement of ED vasodilatation.
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